About the Report
Download the Beacon mAbs Report to stay updated on the latest developments in the field. Interest in mAbs has grown exponentially, and the report covers the latest findings. Don’t miss out on valuable insights for your drug development strategies.
The report includes:
- An in-depth analysis of the current drug and trial landscape showcasing the shifts in focus and development phases.
- Beacon Immune Tolerance is currently tracking 2,831 trials that investigate mAbs in immune-mediated diseases. The report provides detailed information on the phase and status of these trials.
- The report explores the average time to trial completion, the top 5 clinical diseases being investigated, immunogenicity and much more.
Beacon Immune Tolerance
How the most complete immune tolerance database can help you
What we cover
Beacon Immune Tolerance covers all pharmaceutical interventions used to treat autoimmune diseases, autoinflammatory diseases, alloimmune diseases and allergies.
The solution encapsulates all drugs and therapies within the immune-mediated disease space from small molecules to CAR T therapy.
Our unique Milestones filter and visualization highlights past, present, and future drug development milestones including drug and trial readouts, asset history, and regulatory announcements. This enhancement provides an accurate, timely and exhaustive single-drug timeline allowing you to benchmark progress in the immune tolerance space
How Beacon Immune Tolerance works
All Immune Tolerance pages will have unique data fields that will help speed up the research process. These data fields include:
- Autoantigen specificity
- Mechanism of Action
- Cell Source
- Cell Type
- Delivery System
- Editing Technology
- Target Organ/Cell